Insmed, a biotech firm, has received Food and Drug Administration clearance for Brensocatib, a daily pill treating bronchiectasis. Estimated peak sales of $5 billion could make it a growth driver and propel the company into major biotech status.
Source: https://www.statnews.com/2025/08/12/insmed-lung-disease-drug-approved